The *Trypanosoma brucei gambiense* Secretome Impairs Lipopolysaccharide-Induced Maturation, Cytokine Production, and Allostimulatory Capacity of Dendritic Cells

Edwin Garzón,* Philippe Holzmuller,* Rachel Bras-Gonçalves,* Philippe Vincendeau,b Gérard Cuny,* Jean Loup Lemesre,a Anne Geiger*

UMR 177, IRD-CIRAD, Montpellier, France; Laboratoire de Parasitologie, Université Victor Segalen Bordeaux II, Bordeaux, France

*Correspondence can be addressed to Anne Geiger, anne.geiger@ird.fr.

Editor: J. F. Urban, Jr.

Received 29 January 2013 Returned for modification 26 February 2013 Accepted 17 June 2013 Published ahead of print 24 June 2013

**Abstract**

Human African trypanosomiasis (HAT), or sleeping sickness, is caused by *Trypanosoma brucei gambiense* and *Trypanosoma brucei rhodesiense*, extracellular eukaryotic flagellate parasites transmitted by tsetse flies (*Glossina* spp.). Infection with *T. b. gambiense* gives rise to the chronic form of sleeping sickness in West and Central Africa, whereas infection with *T. b. rhodesiense* results in the acute form of sleeping sickness in East Africa. If left untreated, both forms of the disease are fatal (1). Treatment of the disease is difficult and may have potentially life-threatening side effects (1–6). To date, no prophylactic chemotherapy and no prospect of a vaccine are in view. Therefore, novel therapeutic targets for fighting the parasite are urgently needed. This requires a clear understanding of the different factors involving host characteristics and the intrinsic properties of the parasite, such as its ability to escape the host immune system.

Trypanosomes of the *T. brucei* group cause many immune system disorders. The most striking biological phenomenon is the ability of the trypanosome to keep changing its surface antigenic coat (variant surface glycoprotein [VSG]) (7), which allows evasion of the host’s defense mechanisms by inducing polyclonal activation of B cells (8). Moreover, during trypanosomiasis, nonspecific polyclonal activation of B and T lymphocytes is associated with immunosuppression, facilitating parasite evasion, survival, and dissemination (8, 9).

A class of proteins that is particularly noteworthy with respect to immunomodulation is the excreted-secreted proteins (ESPs), among which several were analyzed individually and were shown to be involved in various aspects of the virulence process or pathogenesis (10–13). For instance, trypanosome-secreted proteins induce macrophage arginase, a hallmark of macrophage alternative activation (12), indicating their potency as paracrine modulators.

The initial recognition of an invading pathogen by antigen-presenting cells (APCs) is crucial in regulating innate and adaptive immune responses. Given their unique and essential function in the initiation of the acquired immune response (14), dendritic cells (DCs) have been demonstrated to be the primary cell population responsible for activating naive VSG-specific Th-cell responses in a tissue-specific manner (15). DC maturation is associated with increased expression of major histocompatibility complex (MHC) and other costimulatory molecules (CD40, CD80, CD86) that enhance the proliferation of naïve T cells, while DC activation is related to the production of inflammatory cytokines that regulate T-cell differentiation (16). Interestingly, resistance to trypanosome infection was associated with upregulation of costimulatory molecules, secretion of interleukin-12 (IL-12), and presentation of VSG peptides to T cells in vivo (15). However, tumor necrosis factor alpha (TNF-α)- and nitric oxide (NO) synthase 2-producing DCs are responsible for trypanosome infection-associated pathogenesis (17), but the regulation of DC populations appears to be even more complex, since *T. brucei* VSG or TNF-α was shown to induce partial maturation of DCs, generating a default Th2-cell differentiation response, whereas lipopolysaccharide (LPS)-induced full maturation of the same DCs was shown to generate a Th1-cell response (18).

To better understand the mechanisms that underlie the host immune system disorders primed through DC population mod-

---

**The Trypanosoma brucei gambiense Secretome Impairs Lipopolysaccharide-Induced Maturation, Cytokine Production, and Allostimulatory Capacity of Dendritic Cells**

*Trypanosoma brucei gambiense*, a parasitic protozoan belonging to kinetoplastids, is the main etiological agent of human African trypanosomiasis (HAT), or sleeping sickness. One major characteristic of this disease is the dysregulation of the host immune system. The present study demonstrates that the secretome (excreted-secreted proteins) of *T. b. gambiense* impairs the lipopolysaccharide (LPS)-induced maturation of murine dendritic cells (DCs). The upregulation of major histocompatibility complex class II, CD40, CD80, and CD86 molecules, as well as the secretion of cytokines such as tumor necrosis factor alpha, interleukin-10 (IL-10), and IL-6, which are normally released at high levels by LPS-stimulated DCs, is significantly reduced when these cells are cultured in the presence of the *T. b. gambiense* secretome. Moreover, the inhibition of DC maturation results in the loss of their allostimulatory capacity, leading to a dramatic decrease in Th1/Th2 cytokine production by cocultured lymphocytes. These results provide new insights into a novel efficient immunosuppressive mechanism directly involving the alteration of DC function which might be used by *T. b. gambiense* to interfere with the host immune responses in HAT and promote the infectious process.
ulation in a *T. b. gambiense* infection, we investigated the effects of the secretomes of two different *T. b. gambiense* strains on LPS-induced maturation and activation of murine DCs. We chose the model of DCs stimulated by LPS, a Toll-like receptor 4 (TLR4) ligand that has been shown to be a saliva component modulating the host innate immune response through a vector bite in different models (19–21), to dissect the effect of the trypanosome’s secretome in the context of tsetse fly transmission. Our ex vivo data show that *T. b. gambiense* secretomes impair the LPS-induced maturation of DCs and inhibit the DC-mediated secretion of pro-inflammatory cytokines required to activate the host immune system to fight the parasite.

**MATERIALS AND METHODS**

**Mice and rats.** Female BALB/c (H-2^d^) and C57BL/6 (H-2^b^) mice aged 6 to 8 weeks and male Wistar rats aged 6 to 12 weeks were purchased from Charles River Laboratories (L’Arbresle, France). All animal experiments were conducted according to Centre de Coopération Internationale en Recherche Agronomique pour le Développement (CIRAD) institutional guidelines; the protocols were submitted to and approved by the Ethics Committee on Animal Experimentation at the CIRAD, Montpellier, France.

**Trypanosomes and secretomes.** Trypanosome bloodstream strains FEO (ITMAP 1893 MHOM R) and OK (ITMAP 1841) (22, 25) were used for the experiments. The parasites were intraperitoneally injected into rats. When their multiplication reached the logarithmic growth stage, the parasites were purified from blood by chromatography on a DEAE-cellulose column, as previously described (24). The parasites were resuspended at a concentration of 200 × 10^6^ cells/ml in a secretion buffer (Ringer lactate; glucose, 0.6%; KCl, 0.4%; NaHCO3, 0.125%; L-glutamine, 2 mM; minimal essential medium nonessential amino acids, pH 8) (12) and incubated at 37°C in 5% CO2 for 2 h. Every 15 min, parasite viability was controlled by microscopic examination and quantitated by flow cytometric analysis using the DNA intercalant propidium iodide (PI), as recommended by the manufacturer (Immunotech, Marseille, France). Parasite viability was always high (in general, nearly 98%) and remained constant for 2 h. In addition, only one peptide of VSG supported by a very low peptide score [36] was sequenced by tandem mass spectrometry (MS/MS) in secretomes (25). In mass spectrometry, proteins supported by only one peptide are not considered valid. This means that VSG was not identified in the secretome fractions used for the experiments. One may conclude that the extracellular proteins present in the trypanosome incubation medium are really secreted proteins and not proteins released into the medium after lysis of the parasites. At the end of the experiment, the reaction was stopped by centrifugation of parasites at 1,000 × g for 10 min. The supernatant was collected and filtered on a 0.2-μm-pore-size filter and immediately aliquoted and frozen at −80°C.

**One-dimensional electrophoretic analysis.** Proteins from the different secretome samples (FEO and OK strains) were heated at 100°C for 2 min and spun for 5 min at 14,000 × g prior to separation by one-dimensional (1-D) sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Proteins were separated on 24- by 18-cm Tricine-SDS-polyacrylamide gels (12% acrylamide) (26). After migration, the gels were fixed and proteins were visualized by Coomassie brilliant blue R-250. Images of the gels were taken with a high-resolution scanner (Amersham Biosciences).

**Generation of mouse BMDCs and spleen cells.** The culture medium medium R5 consists of RPMI 1640 medium (Perbio Science, Brembieres, France) supplemented with 10% heat-inactivated fetal bovine serum (Perbio Science), 2 mM L-glutamine, 0.1 mM nonessential amino acids, 30 μM β-mercaptoethanol (Sigma-Aldrich Chimie, Lyon, France), 100 IU/ml penicillin, 100 μg/ml streptomycin, and 1 mM sodium pyruvate (Life Technologies). Immature bone marrow-derived dendritic cells (BMDCs) were obtained by flushing the tibias and femurs of BALB/c mice with RPMI 1640 medium and passing bone marrow through a nylon membrane (cell strainer; Dutscher, Cergy, France) as described by Inaba et al. (27). After red blood cell lysis with ammonium chloride, T and B cells were depleted using mouse pan-T and pan-B Dynabeads (Life Technologies, Saint-Aubin, France), and monocytes were removed by adherence for 3 h at 37°C under 5% CO2 in R5 medium. Nonadherent cells (5 × 10^5^ cells/ml) were collected and further cultured for differentiation in 24-well plates for 6 days in R5 medium containing 1,000 IU/ml recombinant mouse granulocyte-macrophage colony-stimulating factor (rGM-CSF) and 1,000 IU/ml recombinant mouse interleukin-4 (rIL-4) (R&D Systems, Lille, France). At day 7, the cell population contained at least 70% CD11c^+^ cells, determined by flow cytometry analysis using a FACS caliber flow cytometer (BD Biosciences, Le Pont de Claix, France), and these were considered differentiated cells. These cells were collected and placed for maturation (10^5^ cells/ml) in 24-well plates containing R5 medium supplemented with either 10 ng/ml LPS (in the presence or absence of 10 μg/ml polymyxin B preincubated for 1 h at 37°C with LPS), 5 μg/ml T. b. gambiense secretome, or both for 24 h at 37°C. Control cells were cultured in R5 medium alone or in R5 medium supplemented with secretion medium.

Spleen cells were obtained by spleenectomy of C57BL/6 mice and spleen dissociation in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum (Perbio Science, Brembieres, France), 100 IU/ml penicillin, and 100 μg/ml streptomycin (Life Technologies). After passage through a nylon membrane (cell strainer; Dutscher), red blood cells were lysed with ammonium chloride. Spleen cell viability was assessed by the trypan blue dye exclusion test and was over 97%. Spleen cells were further cocultured with BMDCs in the mixed lymphocyte reaction (MLR).

**Cell phenotyping and FACS analysis.** All monoclonal antibodies (MAbs) used for cell phenotyping by flow cytometry were purchased from Becton, Dickinson-Pharmingen (Le Pont de Claix, France). Briefly, immunostaining was performed using MAbs conjugated to fluorescein isothiocyanate (FITC) or phycoerythrin (PE), anti-CD40-FITC (3/23, rat IgG2a), anti-CD80-FITC (B7-1/16-10A1, hamster IgG2), anti-CD86-FITC (B7-2/GL1, rat IgG2a), anti-CD11c-FITC (HL3, hamster IgG1), anti-major histocompatibility complex class II (anti-MHC-II)-PE (1-E1, mouse IgG2a), and control isotypes (rat IgG2a, hamster IgG1 and IgG2, mouse IgG2a). After stimulation with either LPS, the *T. b. gambiense* secretome, or both, BMDCs from BALB/c mice were collected in phosphate-buffered saline (PBS; Life Technologies) containing 0.1% bovine serum albumin (BSA; Life Technologies) and 0.1% NaN3 (Sigma-Aldrich Chimie) and incubated with MAbs for 30 min at 4°C. After two rounds of washing in PBS-BSA-NaNO₃, 10,000 cells were analyzed per sample in triplicate. Fluorescence-activated cell sorting (FACS) data were collected and analyzed on a FACS caliber flow cytometer (BD Biosciences) using CellQuest Pro software. The results are expressed as the percentage of cells gated in the peak of fluorescence (M1) for each cell surface marker histogram plot.

**Mixed lymphocyte reaction.** BMDCs from BALB/c mice stimulated with LPS, the *T. b. gambiense* secretome, or both were used as stimulator cells, and spleen cells from C57BL/6 mice were used as responder cells. Stimulator BMDCs were incubated for 5 days at 37°C under 5% CO2 with allogeneic spleen cells in 96-well plates containing 0.2 ml R5 medium per well at a 1:30 stimulator/responder cell ratio (control wells contained unstimulated BMDCs). After centrifugation, the supernatant was collected and kept at −80°C for cytokine production measurement. Cell proliferation was evaluated by a nonradioactive enzyme-linked immunosorbent assay (ELISA) technique using a monoclonal antibody against 5-bromo-2-deoxyuridine (BrdU) (28), which was added for 18 h on day 4, and revealed by an enzyme-conjugated second antibody, according to the manufacturer’s instructions (BrdU cell proliferation detection kit III; Boehringer-Mannheim, Germany). The absorbance at 405 nm was read in
an ELISA plate reader (Labsystems Multiscan EX). Proliferative responses were expressed as splenocyte proliferation indexes, which represent the ratio between the mean ± standard deviation (SD) of the optical densities obtained with stimulated BMDCs (LPS in the presence or absence of trypanosome secretome) and the mean ± standard deviation of the optical densities obtained with unstimulated cultured BMDCs.

**Cytokine quantification.** IL-10, TNF-α, and IL-6 in culture supernatants (50 μl) of BMDCs exposed for 48 h to the following stimuli were quantified using a BD cytometric bead array (CBA) mouse inflammation kit (BD Biosciences): LPS (10 ng/ml) with secretion medium or *T. b. gambiense* secretome (5 μg/ml). The IL-2, IL-4, IL-5, gamma interferon (IFN-γ), and TNF-α in the culture supernatants (50 μl) of the allogeneic MLR assays were quantified after 5 days using a BD CBA mouse T helper (Th1/Th2) cytokine kit (BD Biosciences). Data were acquired by flow cytometry (FACSCalibur) using two-color detection and analyzed by BD Bioscience cytometric bead array software according to the manufacturer’s instructions (BD Biosciences).

**Statistical analyses.** Data are presented as the mean ± standard deviation of triplicates from at least two independent experiments. Statistical significance was analyzed using the Student t test; P values are indicated for each histogram.

**RESULTS**

**One-dimensional electrophoresis protein profiling of the secretomes.** The profiles generated by the electrophoretic separation of the secretome proteins from the two bloodstream parasite strains (OK and FEO) are shown in Fig. 1. A high number of bands were separated, and these corresponded to proteins with molecular masses ranging from 7 to 150 kDa.

Visual observation of the 1-D gels showed similarities, as well as some quantitative and qualitative differences, between the secretome profiles of the two parasite strains. Protein identifications have previously been investigated, and proteins were classified into 12 functional categories, including the folding and degradation, nucleotide metabolism, and hypothetical protein categories (25).

The *T. b. gambiense* secretome inhibits CD40 and MHC-II expression in BMDCs. Since maturation is an essential process during which DCs acquire optimal immunostimulatory properties, we examined the effect of the *T. b. gambiense* secretome, a paracrine immunomodulating compartment of trypanosomes, on the response of BMDCs to LPS, which has previously been described to be a major stimulus for cytokine production and upregulation of surface molecule expression (29, 30). Figure 2 depicts the analytical strategy followed for phenotyping the mouse BMDCs differentiated in culture, which were first gated in R1 (n = 10,000 cells) according to cell size and granulometry (forward scatter/side scatter [FSC/SSC] dot plot; Fig. 2A); these cells were then gated in R2 according to positivity for CD11c (a cell surface marker expressed by murine DCs) (Fig. 2B). This gated cell population (n = 7,000 cells) was then analyzed for MHC class II molecule and CD40, CD80, and CD86 costimulatory molecule expression. The levels of all phenotypic markers were increased upon LPS stimulation, as shown by the change in the fluorescence intensity of the corresponding markers in the M1 statistical interval (Fig. 2C and D), which was then used to calculate the percentage of cells positive for each experimental condition. Contrary to LPS, the secretion medium or the secretomes of *T. b. gambiense* alone, as well as polymyxin B, had no effect on the levels of expression of BMDC MHC class II molecules or the costimulatory mol-
ecules (CD40, CD80, and CD86), similar to control BMDCs cultured in R5 medium alone (Fig. 3A and Table 1; see Fig. S1 in the supplemental material). We next evaluated the effect of T. b. gambiense secretomes on DC maturation by looking for phenotypic changes in BMDCs exposed to LPS. LPS alone markedly induced the expression of MHC class II and all costimulatory molecules (CD40, CD80, and CD86) by BMDCs compared to that by control BMDCs (Fig. 3A). In contrast, a dramatic inhibition of the LPS-

**FIG 3** T. b. gambiense secretomes modulate the phenotype of immature BMDCs. (A) After stimulation with LPS in the presence or absence of the T. b. gambiense secretome, BMDCs from BALB/c mice were collected in PBS containing 0.1% bovine serum albumin and 0.1% NaN₃, and incubated with MAbs for 30 min at 4°C. BMDCs gated for CD11c positivity (R2; Fig. 2) were analyzed for changes in CD40, CD80, CD86, and MHC class II molecule expression levels (mean ± SD of the percentage of cells gated in M1; Fig. 2; Table 1). (B) TNF-α, IL-10, and IL-6 in culture supernatants of BMDCs exposed to the following stimuli for 48 h were quantified using a BD CBA mouse inflammation kit: LPS with or without T. b. gambiense secretomes. Data were acquired by flow cytometry (FACSCalibur), were analyzed by BD Bioscience cytometric bead array software according to the manufacturer’s instructions, and are presented as the mean ± SD cytokine concentration (pg/ml; Table 2). For both panels A and B, cells in culture medium alone (BMDCs) were used as a negative control, and those supplemented with LPS were used as a positive control. Data are presented as the mean ± SD of triplicates from three independent experiments. Statistical significance was analyzed using the Student t test; P values are indicated for each histogram.

**TABLE 1** Changes in levels of CD40, CD80, CD86, and MHC-II molecule expression by CD11c⁺ BMDCs

<table>
<thead>
<tr>
<th>Stimulator</th>
<th>Mean % ± SD BMDCs gated in M1 expressingᵃ</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMDCs</td>
<td>Control Ab  2.97 ± 0.91</td>
</tr>
<tr>
<td>BMDCs + OK secreteme</td>
<td>CD40  3.32 ± 0.16</td>
</tr>
<tr>
<td></td>
<td>CD80  3.43 ± 0.11</td>
</tr>
<tr>
<td></td>
<td>CD86  32.67 ± 2.82</td>
</tr>
<tr>
<td></td>
<td>MHC-II  12.7 ± 0.93</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>BMDCs + FEO secreteme</td>
<td>CD40  3.1 ± 0.43</td>
</tr>
<tr>
<td></td>
<td>CD80  3.27 ± 0.54</td>
</tr>
<tr>
<td></td>
<td>CD86  35.17 ± 2.85</td>
</tr>
<tr>
<td></td>
<td>MHC-II  9.54 ± 3.05</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>BMDCs + OK secreteme + LPS</td>
<td>CD40  2.63 ± 1.21</td>
</tr>
<tr>
<td></td>
<td>CD80  3.57 ± 0.58</td>
</tr>
<tr>
<td></td>
<td>CD86  32.47 ± 4.22</td>
</tr>
<tr>
<td></td>
<td>MHC-II  16.19 ± 3.99</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>BMDCs + FEO secreteme + LPS</td>
<td>CD40  2.7 ± 1.05</td>
</tr>
<tr>
<td></td>
<td>CD80  3.59 ± 0.61</td>
</tr>
<tr>
<td></td>
<td>CD86  33.47 ± 3.42</td>
</tr>
<tr>
<td></td>
<td>MHC-II  14.43 ± 3.06</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>BMDCs + LPS</td>
<td>CD40  2.48 ± 0.78</td>
</tr>
<tr>
<td></td>
<td>CD80  18.83 ± 1.17</td>
</tr>
<tr>
<td></td>
<td>CD86  45.38 ± 0.78</td>
</tr>
<tr>
<td></td>
<td>MHC-II  27.42 ± 4.16</td>
</tr>
</tbody>
</table>

ᵃ Percentage of cells gated in M1 in Fig. 2.
induced maturation of BMDCs was observed in the presence of *T. b. gambiense* secretomes according to the levels of expression of the CD40, CD80, CD86, and MHC class II molecules (Fig. 3A). The inhibitory effect was similar to that of polymyxin B (see Fig. S1 in the supplemental material), a well-described chelator of LPS-type endotoxin (31). Interestingly, whereas the inhibitory effect of the *T. b. gambiense* secretome on the expression of CD40 and CD80 was total, there were statistically significant slight differences in the effect of the secretome on the expression of CD86 and MHC class II molecules depending on the strain of *T. b. gambiense* from which the secretome originated. The secretomes of the OK and FEO strains exhibited a weak direct inhibitory effect on CD86 expression by BMDCs but seemed to be less efficient than the other markers in inhibiting LPS-induced CD86 expression (Fig. 3A). Moreover, the secretome of the OK strain showed a better inhibitory effect on MHC class II molecule expression than the secretome of the FEO strain (Fig. 3A).

The *T. b. gambiense* secretome inhibits cytokine production by BMDCs. To confirm the inhibitory effect of the *T. b. gambiense* secretome on DC maturation, the cytokine profile of stimulated BMDCs was determined. At first, the secretomes of *T. b. gambiense* alone had no effect on BMDC cytokine production, with the levels of production being similar to those for the control BMDCs cultured in R5 medium alone (data not shown). Immature BMDCs from BALB/c mice stimulated with LPS displayed increased expression of TNF-α, IL-10, and IL-6 (Fig. 3B and Table 2). Interestingly, the LPS stimulation was significantly inhibited in the presence of *T. b. gambiense* secretomes, as indicated by a significant decrease in the production of TNF-α (2-fold, \( P < 0.001 \)), IL-10 (2-fold, \( P < 0.02 \)), and IL-6 (3-fold, \( P < 0.001 \)) (Fig. 3B). The inhibitory effect of the *T. b. gambiense* secretome was independent of the parasite strain considered (Fig. 3B). Taken together with phenotyping data, these data show that the *T. b. gambiense* secretome inhibits DC functional maturation.

The *T. b. gambiense* secretome inhibits the allostimulatory capacity of BMDCs and Th1/Th2 cytokine production by cocultured lymphocytes. The function of DCs can be further characterized by an ability to stimulate alloreactive (naive) spleen cells (32). A mixed lymphocyte reaction (MLR) was performed using BALB/c mouse BMDCs stimulated with LPS in the presence or absence of the *T. b. gambiense* secretomes as stimulator cells and cocultured spleen cells from C57BL/6 mice as responder cells. BMDCs stimulated with LPS alone induced spleen cell proliferation, as indicated by a splenocyte proliferation index higher than 2 (Fig. 4). In contrast, whatever the secretome of *T. b. gambiense* considered, the secretome completely abolished the allostimulatory capacity of LPS-stimulated BMDCs, as indicated by a splenocyte proliferation index of 1 (Fig. 4).

To confirm the impairment of BMDC immunomodulating properties, Th1 and Th2 cytokines in culture supernatants from C57BL/6 mouse spleen cells stimulated with BALB/c mouse BMDCs exposed to LPS in the presence or absence of the *T. b. gambiense* secretomes were quantified at 48 h. The pattern of Th1 cytokine (IFN-γ, IL-2, and TNF-α) expression by C57BL/6 mouse spleen cells was dramatically inhibited in cells stimulated by BMDCs exposed to LPS in the presence of *T. b. gambiense* secretomes (Fig. 5A and Table 3). A 2-fold inhibition of IL-2 production by allogeneic splenocytes was observed for cells cocultured with BMDCs stimulated with LPS in the presence of *T. b. gambiense* secretomes compared to the level of production for cells stimulated with LPS alone (Fig. 5A). For IFN-γ and TNF-α production, inhibition differed according to the *T. b. gambiense* secretome: the inhibitory effect of the FEO strain’s secretome was less efficient than that of the OK strain’s secretome (Fig. 5A).

In the same way, Th2 cytokine production (IL-4 and IL-5) by allogeneic splenocytes was significantly inhibited (about 4-fold) by *T. b. gambiense* secretomes (\( P < 5 \times 10^{-5} \)) (Fig. 5B). IL-4 production was fully inhibited in cells cocultured with BMDCs stimulated by LPS in the presence of the *T. b. gambiense* secretome, whatever the strain considered (Fig. 5B). For IL-5 production, the inhibitory effect induced by the FEO strain’s secretome was not complete (\( P \approx 0.001 \)) compared to that induced by the OK strain’s secretome (Fig. 5B).

**DISCUSSION**

The inoculation of African trypanosomes into their mammalian hosts triggers a series of events involving, primarily, innate immunity and, secondarily, specific immunity. In experimental models, immunosuppression was attributed to polyclonal B-cell activation induced by continuous complex antigenic variation through VSG switching to circumvent host antibody targeting, as well as the generation of suppressor T cells or a defect in the T-cell pop-

---

**TABLE 2 Concentrations of cytokines secreted by CD11c<sup>+</sup> BMDCs**

<table>
<thead>
<tr>
<th>Stimulator</th>
<th>Mean concn (pg/ml) ± SD</th>
<th>TNF-α</th>
<th>IL-10</th>
<th>IL-6</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMDCs</td>
<td>235.1 ± 5.01</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BMDCs + OK secretome + LPS</td>
<td>2,176.47 ± 117.65</td>
<td>44.62 ± 3.07</td>
<td>525 ± 15</td>
<td></td>
</tr>
<tr>
<td>BMDCs + FEO secretome + LPS</td>
<td>1,941.18 ± 176.47</td>
<td>50.26 ± 0.03</td>
<td>475 ± 25</td>
<td></td>
</tr>
<tr>
<td>BMDCs + LPS</td>
<td>5,352.94 ± 352.94</td>
<td>128.23 ± 21.51</td>
<td>1,400 ± 75</td>
<td></td>
</tr>
</tbody>
</table>

FIG 4 Ability of differentiated BMDCs to stimulate allogeneic T cells. BMDCs from BALB/c mice cultured in medium alone or incubated with LPS in the presence or absence of *T. b. gambiense* secretomes were used as stimulator cells, and spleen cells from C57BL/6 mice were used as responder cells. The proliferative response of splenocytes was measured by ELISA after BrdU incorporation and is expressed as the cell proliferation index. Data are presented as the mean ± SD of triplicates from two independent experiments. Statistical significance was analyzed using the Student t test; \( P \) values are indicated for each histogram.
TABLE 3 Concentrations of cytokines secreted by splenocytes in MLR

<table>
<thead>
<tr>
<th>Stimulator</th>
<th>Mean concn (pg/ml) ± SD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>IFN-γ</td>
</tr>
<tr>
<td>BMDGs</td>
<td>127.26 ± 6.02</td>
</tr>
<tr>
<td>BMDGs + OK secretome + LPS</td>
<td>97.07 ± 8.01</td>
</tr>
<tr>
<td>BMDGs + FEO secretome + LPS</td>
<td>170.41 ± 15.02</td>
</tr>
<tr>
<td>BMDGs + LPS</td>
<td>300 ± 20</td>
</tr>
</tbody>
</table>

FIG 5  T. brucei secretomes inhibit Th1/Th2 cytokine production. IFN-γ, IL-2, and TNF-α (A) and IL-4 and IL-5 (B) in the culture supernatants of the allogeneic MLR assays were quantified after 5 days using a BD CBA mouse T helper (Th1/Th2) cytokine kit. Data were acquired by flow cytometry (FACS Calibur), were analyzed by BD Bioscience cytometric bead array software according to the manufacturer’s instructions, and are presented as the mean ± SD cytokine concentration (pg/ml; Table 3). Cells in culture medium alone (BMDGs) were used as a negative control, and those supplemented with LPS were used as a positive control. Data are presented as the mean ± SD of triplicates from four independent experiments. Statistical significance was analyzed using the Student t test; P values are indicated for each histogram.

TABLE 3 Concentrations of cytokines secreted by splenocytes in MLR

Elimination (40). In a trypanosome infection, DCs play a crucial role in the activation of Th-cell responses, with DCs being the primary cell population inducing a VSG-specific response in naive T cells (15). However, VSG induces partial maturation of DCs, leading to a Th2-cell response that does not exert antitrypanosome activity (18). Recently, natural killer T cells and regulatory T cells have been demonstrated to influence the outcome of a trypanosome infection (41–43). Moreover, trypanosomes are also capable of reducing B lymphopoiesis and selectively destroying B-cell populations (44, 45). The previous short description of immunological disorders induced by trypanosomes makes one believe that the trypanosome has developed a strategy of communication through paracrine mediators to dysregulate immune functions in a discrete manner, in addition to the powerful mechanism of VSG switching. This is why in the present study we investigated the effects of the T. b. gambiense secretome on both maturation of DCs and their immunomodulating functions. We demonstrated that the trypanosome secretome inhibited functional maturation and activation of BMDCs and impaired promotion of the Th-cell response in the mouse model. The secretome exerted suppressive activity on LPS-stimulated DCs by inhibiting the expression of CD40, CD80, CD86, and MHC class II molecules, as well as allostimulatory activity.

We chose stimulation by LPS not only because it is a well-established biological interaction tool in fundamental immunology but also because it seems to participate in the trypanosome’s strategy to enslave the immune system of the host. During natural infection, the presence of bacteria on the mammal’s skin or in the digestive tract of the insect vector (46–49) might provide exogenous LPS through a tsetse fly bite of the mammal’s skin, and the exogenous LPS may further participate in host immune system dysregulation. For instance, it has been proven that the level of LPS-binding protein (LBP) increased in the plasma of mice infected by Trypanosoma brucei, which can enhance the cellular responses of the infected host to LPS (50). Interestingly, in the expression site containing the serum resistance-associated (SRA) gene, there is an expression site-associated gene (ESAG5) that indicated a possible relationship to the LBP family (51). These elements argue in favor of the hypothesis that the trypanosome uses LPS to immunomodulate the cells of the host immune system to its advantage.

The extracellular location of African trypanosomes involves strong molecular cross talk with host immune cells, which occurs through cell-cell contact or excreted-secreted factors exhibiting immunomodulatory properties. In previous experiments aiming at identifying the trypanosome’s secretome components (26), we could assign 50% of the proteins to three major categories: protein folding and degradation, nucleotide metabolism, and unassigned functions. Forty percent of the remaining proteins fell into one of five categories: carbohydrate metabolism, amino acid metabo-
lism, protein synthesis, signaling, and cell cycle and cell organization. Moreover, the secretome appeared to be unexpectedly rich in various peptidases covering more than 10 peptidase families or subfamilies, among which some could play a role in pathology (52–54). Even though the functions of the secretome identified are not involved in parasite physiology, previous evidence exists for their potential involvement in mechanisms of enslavement of the host. For instance, a paracrine factor synthesized by trypanosomes was described to trigger IFN-γ production by CD8⁺ T cells and act as a growth factor (55). IFN-γ also induces classical macrophage activation that leads to production of cytokotoxic factors, such as nitric oxide (NO) and reactive oxygen species (ROS), which are trypanostatic but at the same time enhance immunosuppression and alter the blood-brain barrier (8). Few T. brucei-derived factors that modulate the innate immune response have been identified. The glycosylphosphatidylinositol anchor of VSG, CpG oligodeoxynucleotides, and the trypanosome-suppressive immunomodulating factor (TSIF) induce TNF-α and NO-secreting M1 cells (56–58). These factors might favor the control of parasite development in the early stage of infection; however, their continuous release in the late stage of infection can maintain inflammation and induce tissue pathogenicity. It was well described that the production of IFN-γ by polarized T cells contributed to early host resistance during infection and that VSG-specific T-cell responses acted through the activation of macrophages to produce trypanocidal factors such as reactive oxygen intermediates, reactive nitrogen intermediates, and TNF-α (38, 59, 60). In addition to a sequential effect of IFN-γ, it is also noteworthy that soluble VSG can inhibit the responsiveness of macrophages to IFN-γ (61) and that this inhibition could be a strategy to limit the immunopathological effects induced by the antitrypanosomal immunoreactive response (62). We also demonstrated that soluble factors from T. brucei induced arginase expression and activity and antagonized brucei inducible NO synthase (NOS)-mediated conversion of L-arginine into NO induced arginase expression and activity and antagonized brucei synthase (NOS)-mediated conversion of L-arginine into NO induced arginase expression and activity and antagonized brucei inducible NO synthase (NOS)-mediated conversion of L-arginine into NO induced arginase expression and activity and antagonized brucei inducible NO synthase (NOS)-mediated conversion of L-arginine into NO induced arginase expression and activity and antagonized brucei inducible NO synthase (NOS)-mediated conversion of L-arginine into NO induced arginase expression and activity and antagonized brucei inducible NO synthase (NOS)-mediated conversion of L-arginine into NO induced arginase expression and activity and antagonized...
mune downregulation for the survival of parasites and/or the regulation of immunopathogenesis. Finally, the identification of the factor(s) in the *T. b. gambiense* secretome and of the DC receptor(s) involved might uncover new therapeutic targets that may be used to fight against sleeping sickness.

ACKNOWLEDGMENTS

This investigation received financial support from the Institut de Recherche pour le Développement (IRD), Centre de Coopération Internationale en Recherche Agronomique pour le Développement (CIRAD).

We acknowledge Pascale Louis-Plencé (INSERM) for precious help and fruitful discussions.

REFERENCES


